The FDA authorized Antares Pharma's oxybutynin, a topical gel for overactive bladder, in 84-milligram strength. Antares partner Watson Pharmaceuticals expects to launch the treatment next year.
Antares gets FDA OK of topical bladder drug oxybutynin
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||